<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="correction" dtd-version="1.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id>
<journal-title-group>
<journal-title>Frontiers in Immunology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Immunol.</abbrev-journal-title>
</journal-title-group>
<issn pub-type="epub">1664-3224</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fimmu.2026.1807170</article-id>
<article-version article-version-type="Version of Record" vocab="NISO-RP-8-2008"/>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Correction</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Correction: VEXAS: A review of current understandings and emerging treatment strategies</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Holden</surname><given-names>Robert</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="corresp" rid="c001"><sup>*</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/3064339/overview"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &amp; editing</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Jeelall</surname><given-names>Yogeshraj</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &amp; editing</role>
</contrib>
<contrib contrib-type="author">
<name><surname>McLean-Tooke</surname><given-names>Andrew</given-names></name>
<xref ref-type="aff" rid="aff4"><sup>4</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/1083222/overview"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &amp; editing</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Pathmanathan</surname><given-names>Kylan</given-names></name>
<xref ref-type="aff" rid="aff5"><sup>5</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &amp; editing</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Nolan</surname><given-names>David</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &amp; editing</role>
</contrib>
</contrib-group>
<aff id="aff1"><label>1</label><institution>Clinical Immunology, Royal Perth Hospital</institution>, <city>Perth</city>, <state>WA</state>, <country country="au">Australia</country></aff>
<aff id="aff2"><label>2</label><institution>Haematology, Royal Perth Hospital</institution>, <city>Perth</city>, <state>WA</state>, <country country="au">Australia</country></aff>
<aff id="aff3"><label>3</label><institution>Medical School, University of Western Australia</institution>, <city>Perth</city>, <state>WA</state>, <country country="au">Australia</country></aff>
<aff id="aff4"><label>4</label><institution>Clinical Immunology, Sir Charles Gairdner Hospital</institution>, <city>Perth</city>, <state>WA</state>, <country country="au">Australia</country></aff>
<aff id="aff5"><label>5</label><institution>Rheumatology, Sir Charles Gairdner Hospital</institution>, <city>Perth</city>, <state>WA</state>, <country country="au">Australia</country></aff>
<author-notes>
<corresp id="c001"><label>*</label>Correspondence: Robert Holden, <email xlink:href="mailto:Robert.holden@health.wa.gov.au">Robert.holden@health.wa.gov.au</email></corresp>
</author-notes>
<pub-date publication-format="electronic" date-type="pub" iso-8601-date="2026-02-27">
<day>27</day>
<month>02</month>
<year>2026</year>
</pub-date>
<pub-date publication-format="electronic" date-type="collection">
<year>2026</year>
</pub-date>
<volume>17</volume>
<elocation-id>1807170</elocation-id>
<history>
<date date-type="received">
<day>09</day>
<month>02</month>
<year>2026</year>
</date>
<date date-type="accepted">
<day>09</day>
<month>02</month>
<year>2026</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2026 Holden, Jeelall, McLean-Tooke, Pathmanathan and Nolan.</copyright-statement>
<copyright-year>2026</copyright-year>
<copyright-holder>Holden, Jeelall, McLean-Tooke, Pathmanathan and Nolan</copyright-holder>
<license>
<ali:license_ref start_date="2026-02-27">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
<license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License (CC BY)</ext-link>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
</license>
</permissions>
<related-article id="RA1" related-article-type="corrected-article" ext-link-type="doi" xlink:href="10.3389/fimmu.2025.1644404" journal-id="Front Immunol" journal-id-type="nlm-ta">A Correction on 
<article-title>VEXAS: A review of current understandings and emerging treatment strategies</article-title> By Holden R, Jeelall Y, McLean-Tooke A, Pathmanathan K and Nolan D (2025) <italic>Front. Immunol.</italic>16:1644404. doi:&#xa0;<object-id>10.3389/fimmu.2025.1644404</object-id>
</related-article>
<kwd-group>
<kwd>VEXAS syndrome</kwd>
<kwd>VEXAS</kwd>
<kwd>autoinflamatory diseases</kwd>
<kwd>myeloid cells</kwd>
<kwd>myelodyslastic syndromes</kwd>
</kwd-group>
<counts>
<fig-count count="0"/>
<table-count count="0"/>
<equation-count count="0"/>
<ref-count count="0"/>
<page-count count="2"/>
<word-count count="289"/>
</counts>
<custom-meta-group>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Autoimmune and Autoinflammatory Disorders: Autoinflammatory Disorders</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<p>Following publication of this article, concerns were raised regarding the reuse of copyright-restricted material in <bold>Figure&#xa0;2</bold>.</p>
<p><bold>Figure&#xa0;2</bold> was modified from <bold>Figure&#xa0;1</bold> of <ext-link ext-link-type="uri" xlink:href="https://onlinelibrary.wiley.com/doi/10.1002/ajh.27156">Koster et&#xa0;al.</ext-link>, originally published under an all-rights-reserved copyright. The authors have now obtained permission from the publisher (Wiley) for reuse of the modified figure. The corrected caption of <bold>Figure&#xa0;2</bold> appears below:</p>
<p>&#x201c;UBA1 gene structure, spectrum of mutations identified in VEXAS and UBA1 isoforms. (A) UBA1 gene structure, spanning amino acids 1 to 1058, with various functional domains highlighted in distinct colours. These include the nuclear localization signal (first 11 codons, NLS), the inactive adenylation domain (IAD), the first segment of the active catalytic cysteine (FCCH), the active adenylation domain (AAD), the second segment of the active catalytic cysteine (SCCH), and the C-terminal Ubiquitin Fold Domain (UFD). The diagram also marks representative mutations. (B) Two primary UBA1 isoforms: UBA1a, which begins at methionine 1 (M1, depicted in black), and UBA1b, starting at methionine 41 (M41, shown in green). Additionally, the non-canonical isoform UBA1c is displayed, initiating at methionine 67 (M67, indicated in dark blue). Modified with permission from Koster et&#xa0;al., <italic>Am J Hematol</italic>. (2024) 99(2):284&#x2013;99.&#x201d;</p>
<p>These corrections relate solely to figure licensing and attribution and do not affect the scientific content, interpretation, or conclusions of the article.</p>
<p><bold>Figure&#xa0;3</bold> was modified from Extended Data <bold>Figure&#xa0;7</bold> of Molteni et al., which was published under a CC BY-NC-ND 4.0 licence that does not permit modifications. To ensure compliance with the licence terms <bold>Figure&#xa0;3</bold> has been removed from the manuscript.</p>
<p>These corrections relate solely to figure licensing and attribution and do not affect the scientific content, interpretation, or conclusions of the article.</p>
</body>
<back>
<sec id="s1" sec-type="disclaimer">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec>
<fn-group>
<fn id="n1" fn-type="custom" custom-type="approved-by">
<p>Approved by: <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/111428">Frontiers Editorial Office</ext-link>, Frontiers Media SA, Switzerland</p></fn>
</fn-group>
</back>
</article>